In an exclusive interview with CNBC-TV 18, Kiran Mazumdar Shaw, CMD of Biocon says that Clingene & Syngene to undergo transformation in the business model and would wait for a year before listing the IPO. She also expects Pfizer revenues in the next 24-36 months.
first published: Jan 3, 2011 10:59 am
A collection of the most-viewed Moneycontrol videos.

Live: Will US-Venezuela tensions derail Nifty's upmove? | Oil stocks in focus | Opening Bell

New Year Party Or Year-End Blues? Bulls In Focus| Top Stock Bets & 2026 Outlook| Opening Bell Live

Nifty Trades in a Narrow 100-Point Range on 2025’s Final F&O Expiry | Closing Bell Live

Small-Caps & Risk: What Investors Often Miss
You are already a Moneycontrol Pro user.

